Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular Lymphoma

In Partnership With:

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Bispecific monoclonal antibodies were a big focus of research at the 2019 ASH Annual Meeting, says Kaplan, most of which target CD3 and CD20. Not only were these agents active in aggressive B-cell lymphomas, but they appear to have significant response rates in indolent B-cell lymphomas as well, including in patients who recur after CAR T-cell therapy.

Many of these studies have limited follow-up. However, these agents are expected to be a lot easier to administer in the outpatient setting with somewhat less toxicity than CAR T-cell therapy, says Kaplan. As a result, these agents may become more widely available to the patient populations who need them, Kaplan concludes.

Related Videos
Jorge E. Cortes, MD
R. Lor Randall, MD, FACS
Lisa A. Carey MD, ScM, FASCO
Gregory Vidal, MD, PhD
Joshua Hill, MD, MS
Gary K. Schwartz, MD
Maya Khalil, MD, assistant professor of medicine, Division of Hematology and Oncology, the University of Alabama at Birmingham (UAB), oncologist, O’Neal Comprehensive Cancer Center, UAB Medicine
Jeffery Zonder, MD
Jeffery Zonder, MD
Julie Renee Brahmer, MD
Related Content